BO-112 Injections Tested for Skin Cancer Treatment
A new phase 2b trial found high response rates in patients treated with intralesional BO-112 injections.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Would you prefer non-surgical options for treating skin lesions over traditional surgical procedures?
Researchers have reported that a phase 2b clinical trial achieved a 61 percent composite response rate in patients with basal cell carcinoma using intralesional BO-112. The study evaluated the efficacy and safety of the injections given before standard surgical excision.
Why it matters
This trial sought to determine if local BO-112 injections could serve as a safe and effective pre-surgical intervention for common skin cancers. The high composite response rate suggests a potential new pathway for enhancing outcomes in patients requiring excision.
The study included 50 participants, with 70 percent of low-risk patients and 58 percent of high-risk patients achieving a response. Additionally, 91 percent of all treatment-related adverse events were reported as mild.
The players
European Academy of Dermatology and Venereology
This is a professional non-profit organization that represents dermatologists and venereologists across Europe.
The details
Patients in the trial received three once-weekly intralesional injections of BO-112 followed by complete surgical excision of the tumor. The study aimed to assess the overall tolerability and efficacy of the injection series, recording no severe treatment-related adverse events during the process.
Timeline
The European Academy of Dermatology and Venereology annual meeting occurred from Sept. 30 to Oct. 3, 2026.
The study results were officially presented on Oct. 7, 2026.
The Big Picture
The study findings were released at the European Academy of Dermatology and Venereology annual meeting, which serves as a major venue for presenting new dermatological therapies. The presentation of these trial results at this event follows the standard practice of disseminating phase 2b clinical data to the broader medical community.
This research provides a potential future treatment pathway for patients facing basal cell carcinoma excision. If further trials confirm these results, patients may eventually have access to less invasive pre-surgical options to improve cancer clearance rates.
The takeaway
The phase 2b data demonstrates that intralesional BO-112 is well-tolerated and can yield significant responses in a clinical setting. Future studies will be essential to determine how this therapy compares to current standard-of-care practices for basal cell carcinoma.
Further reading
Learn more about the latest research and advancements in the field of Cancer.
Source note: This article includes information reported by Healthday.
Live Poll
Would you prefer non-surgical options for treating skin lesions over traditional surgical procedures?
